ClinicalTrials.gg
CompletedNCT04386304Updated Mar 23, 2022

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

A Phase 1 interventional study of (+)-Epicatechin in Becker Muscular Dystrophy, sponsored by Epirium Bio Inc.. Completed at 3 sites in United States. Open to male participants aged 16 Years to 59 Years. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Epirium Bio Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
16 Years to 59 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
93rd of 172
22 · median 25
Started
2020
with 13 others
Phase 1
32 of 233
3 open now
Registered
159th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 93rd largest by enrollment of the 172 interventional ones that give a count, is one of 14 that started in 2020, is one of 32 in phase 1, and was the 159th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 16 Years to 59 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, dose escalation study aimed at evaluating the safety, early efficacy and potential biomarkers of (+)-epicatechin in patients with Becker or Becker-like Muscular Dystrophy (BMD).

Read the detailed description

The safety and tolerability of three escalating doses of (+)-epicatechin will be assessed and early effectiveness measured by changes in plasma biomarkers, tissue biomarkers from muscle biopsies, cardiac imaging, and on clinical function assessments of participants' muscle strength. All patients will receive oral (+)-epicatechin for a total duration of approximately 52 weeks. Three doses of (+)-epicatechin will be tested in sequential 2 month periods with total daily doses of 75, 150, and 225 mg/day (+)-epicatechin. Doses will be escalated every 2 months, if tolerated, for the first 6 months of the study. Participants will then continue to receive the highest does they tolerated for an additional 6 months.

03

Conditions studied

  • Becker Muscular Dystrophy
04

Who can participate

Ages eligible
16 Years to 59 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥16 to \<60 years of age.
  2. Genotype confirmation showing a mutation of the dystrophin gene.
  3. Ambulation - participants must show a history of ambulation past the age of 16 years, with continued ambulation thereafter.
  4. If on treatment in the last 12 months, participants must be on a stable dose at screening. Participants cannot start steroids during the study.

Exclusion criteria

EXCLUSION CRITERIA:

  1. A diagnosis of other neurological diseases or presence of relevant somatic disorders that are not related to Becker muscular dystrophy.
  2. Participants with a history of migraine headaches requiring medical attention and active treatment within the past 6 months.
  3. Participants with allergies to chocolate or cocoa.
  4. Surgery or orthopedic injury that might affect muscle strength or function within 3 months before study entry or planned surgery at any time during the study.
  5. Presence of a concomitant neurologic disease (e.g., Parkinson's disease) that could negatively impact mobility or balance.
  6. Symptomatic heart failure ( Class III or IV) or known \<40% by echocardiogram.
  7. Presence of documented intrinsic lung disease (e.g., , pulmonary fibrosis).
  8. Evidence of current liver disease or impairment.
  9. Inadequate renal function.
  10. count, WBC count, and at Screening \<Lower Limit of Normal (LLN).
  11. Surgery or orthopedic injury that might affect muscle strength or function within 3 months before study entry or planned surgery at any time during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Dose escalation of (+)-epicatechin

    Subjects will receive escalating doses of (+)-epicatechin starting at 75 mg/day and progressing to 150 mg/day and 225 mg/day with 2 months treatment duration for each dose. Subjects will continue treatment on the individual's maximum tolerated dose for another 6 months.

    Drug: (+)-Epicatechin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    The TEAEs will be graded using the adult National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

    Time frame: Through study completion, up to 1 year

Secondary outcomes

  1. Change in cardiac function as assessed by cardiac magnetic resonance imaging (MRI)

    Time frame: Through study completion, up to 1 year

  2. Change in cardiac function as assessed by plasma biomarkers [e.g. pro-B-type natriuretic peptide (pro-BNP), nitrates].

    Time frame: Through study completion, up to 1 year

  3. Change in muscle function as assessed by 6-minute walk test (6MWT)

    Time frame: Through study completion, up to 1 year

  4. Change in muscle function as assessed by Time to Run/Walk 10-meter Test (TTRW10)

    Time frame: Through study completion, up to 1 year

  5. Change in muscle function as assessed by Time to 4-stair Climb Test (TT4SC)

    Time frame: Through study completion, up to 1 year

  6. Change in muscle function as assessed by Time to Run/Walk 100-meter Test (TTRW100)

    Time frame: Through study completion, up to 1 year

  7. Change in muscle structure and function as assessed by Western blot analysis of biopsy specimens (e.g. dystrophin expression)

    Time frame: Through study completion, up to 1 year

  8. Change in muscle biomarkers of regeneration in biopsy specimens (e.g. follistatin)

    Time frame: Through study completion, up to 1 year

  9. Change in plasma biomarkers of muscle regeneration (e.g. follistatin, myostatin)

    Time frame: Through study completion, up to 1 year

07

Study locations

3 sites
  • UCLA Dept of Human Genetics
    Los Angeles, California 90095, United States
  • University of California - Davis Department of Physical Medicine and Rehabilitation
    Sacramento, California 95817, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Mar 2022, 19 months.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2020
First posted
May 13, 2020
StartActual
Jul 13, 2020
Primary completionActual
Mar 1, 2022
CompletionActual
Mar 1, 2022
Last update
Mar 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04386304
Lead sponsor
Epirium Bio Inc.
Responsible party
Sponsor
First posted
May 13, 2020
Start date
Jul 13, 2020
Primary completion
Mar 1, 2022
Completion
Mar 1, 2022
Last update
Mar 23, 2022

Study contacts

Chief Medical Officer
study director · Epirium Bio Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: (+)-epicatechin

Start the discussion